South Africa · Delayed Price · Currency is ZAR · Price in ZAc Remgro Earnings Call Transcripts
Fiscal Year 2026
-
Headline earnings surged 38.8% year-over-year, driven by strong performances from Mediclinic, CIVH, Rainbow, and Heineken Beverages, supporting an 80% interim dividend increase. Portfolio simplification and robust cash generation position the group well amid ongoing macroeconomic and geopolitical volatility.
Fiscal Year 2025
-
Headline earnings rose 38.6% year-over-year, driven by strong performances from key portfolio companies and improved capital allocation. Dividends increased, debt was fully repaid, and portfolio simplification advanced. Positive momentum continues despite challenging market conditions.
-
Regulatory approval is progressing, with enhanced commitments leading to Competition Commission support and an Appeals Court decision expected by September. The transaction values Maziv at ZAR 36 billion, includes significant CapEx and BEE commitments, and is expected to improve Remgro's profitability.
-
Strategic focus has shifted to performance optimization, disciplined capital allocation, and sustainability, with 63% of the portfolio in private assets and a strong Africa-centric approach. Growth drivers include Mediclinic’s transformation and CIVH’s fibre expansion, while portfolio simplification and improved underperforming assets should enhance returns.
-
Headline earnings rose 38.7% to ZAR 3.7 billion, driven by strong operational gains in key portfolio companies and a return to profitability at Heineken Beverages. The balance sheet was de-geared, enabling a 20% dividend increase and flexibility for new investments.
Fiscal Year 2024
-
The AGM covered board elections, approval of financials, and strategic updates, with all resolutions passed. Shareholders discussed executive incentives, portfolio optimization, and global risks, while management addressed diversity, ESG, and trade concerns.
-
Headline earnings declined 20% year-over-year due to non-recurring items and a tough macro environment, but the second half saw improved performance and a 10% increase in the annual dividend. Key investments like Mediclinic, Heineken, and CIVH faced challenges, while OUTsurance and RCL Foods delivered strong results.